dalteparin has been researched along with Granulocytic Leukemia in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boeras, A | 1 |
| Lambert, C | 1 |
| Ferrant, A | 1 |
| van den Neste, E | 1 |
| Hermans, C | 1 |
1 other study available for dalteparin and Granulocytic Leukemia
| Article | Year |
|---|---|
Continuous intravenous infusion of a low-molecular-weight heparin during allogenic haematopoietic stem-cell transplantation.
Topics: Acute Disease; Anticoagulants; Female; Hematopoietic Stem Cell Transplantation; Humans; Infusions, I | 2008 |